These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22768101)

  • 1. Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
    Chanvillard C; Millward JM; Lozano M; Hamann I; Paul F; Zipp F; Dörr J; Infante-Duarte C
    PLoS One; 2012; 7(6):e39625. PubMed ID: 22768101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.
    Angelucci F; Batocchi AP; Caggiula M; Frisullo G; Patanella K; Sancricca C; Nociti V; Tonali PA; Mirabella M
    Neuroimmunomodulation; 2006; 13(2):76-81. PubMed ID: 16974110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Mitoxantrone].
    Pericot I; Montalban X
    Neurologia; 2003; 18(6):318-23. PubMed ID: 12838451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological studies of mitoxantrone in primary progressive MS.
    Pelfrey CM; Cotleur AC; Zamor N; Lee JC; Fox RJ
    J Neuroimmunol; 2006 Jun; 175(1-2):192-9. PubMed ID: 16644023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural killer receptors distribution in multiple sclerosis: Relation to clinical course and interferon-beta therapy.
    Martínez-Rodríguez JE; Saez-Borderías A; Munteis E; Romo N; Roquer J; López-Botet M
    Clin Immunol; 2010 Oct; 137(1):41-50. PubMed ID: 20580616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
    Karni A; Balashov K; Hancock WW; Bharanidharan P; Abraham M; Khoury SJ; Weiner HL
    J Neuroimmunol; 2004 Jan; 146(1-2):189-98. PubMed ID: 14698862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of mitoxantrone for the treatment of multiple sclerosis.
    Jain KK
    Expert Opin Investig Drugs; 2000 May; 9(5):1139-49. PubMed ID: 11060734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.
    Stüve O; Kita M; Pelletier D; Fox RJ; Stone J; Goodkin DE; Zamvil SS
    Mult Scler; 2004 Jun; 10 Suppl 1():S58-61. PubMed ID: 15218811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis.
    Hamzehloo A; Etemadifar M
    Arch Iran Med; 2006 Apr; 9(2):111-4. PubMed ID: 16649351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of mitoxantrone and intrathecal triamcinolone acetonide treatment in chronic progressive multiple sclerosis patients.
    Hellwig K; Schimrigk S; Lukas C; Hoffmann V; Brune N; Przuntek H; Müller T
    Clin Neuropharmacol; 2006; 29(5):286-91. PubMed ID: 16960474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.
    Goffette S; van Pesch V; Vanoverschelde JL; Morandini E; Sindic CJ
    J Neurol; 2005 Oct; 252(10):1217-22. PubMed ID: 15834643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Aggressive multiple sclerosis. Definition and specific therapeutic indication].
    Edan G
    Presse Med; 2004 Feb; 33(3):187-91; discussion 192. PubMed ID: 15029034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
    Kopadze T; Dehmel T; Hartung HP; Stüve O; Kieseier BC
    Arch Neurol; 2006 Nov; 63(11):1572-8. PubMed ID: 17101825
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
    Neuhaus O; Wiendl H; Kieseier BC; Archelos JJ; Hemmer B; Stüve O; Hartung HP
    J Neuroimmunol; 2005 Nov; 168(1-2):128-37. PubMed ID: 16171875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis].
    Szwed M
    Postepy Hig Med Dosw (Online); 2014 Feb; 68():198-208. PubMed ID: 24662788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial.
    Nadeau SE
    Neurology; 2006 May; 66(9):1457-8; author reply 1457-8. PubMed ID: 16682694
    [No Abstract]   [Full Text] [Related]  

  • 18. Mitoxantrone for multiple sclerosis.
    Martinelli Boneschi F; Vacchi L; Rovaris M; Capra R; Comi G
    Cochrane Database Syst Rev; 2013 May; (5):CD002127. PubMed ID: 23728638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical follow-up of 411 patients with relapsing and progressive multiple sclerosis 10 years after discontinuing mitoxantrone treatment: a real-life cohort study.
    Chartier N; Epstein J; Soudant M; Dahan C; Michaud M; Pittion-Vouyovitch S; Guillemin F; Debouverie M; Mathey G
    Eur J Neurol; 2018 Dec; 25(12):1439-1445. PubMed ID: 29996003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.
    Debouverie M; Vandenberghe N; Morrissey SP; Anxionnat R; Pittion-Vouyovitch S; Vespignani H; Edan G
    Mult Scler; 2004 Aug; 10(4):407-12. PubMed ID: 15327038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.